DOCSLIB.ORG

Malignant Phyllodes Tumor with Extensive Lipomatous Differentiation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Malignant Phyllodes Tumor with Extensive Lipomatous Differentiation Thomas Jefferson University Jefferson Digital Commons Department of Radiology Faculty Papers Department of Radiology 11-1-2020 Malignant phyllodes tumor with extensive lipomatous differentiation. Jeffrey Landy Thomas Jefferson University Priya Johal Thomas Jefferson University Alexander Sevrukov Thomas Jefferson University Ida Teberian Thomas Jefferson University Jason Shames Thomas Jefferson University Follow this and additional works at: https://jdc.jefferson.edu/radiologyfp Part of the Radiology Commons LetSee next us page know for additional how authors access to this document benefits ouy Recommended Citation Landy, Jeffrey; Johal, Priya; Sevrukov, Alexander; Teberian, Ida; Shames, Jason; Sebastiano, Christopher; and Kaufman, Theresa, "Malignant phyllodes tumor with extensive lipomatous differentiation." (2020). Department of Radiology Faculty Papers. Paper 92. https://jdc.jefferson.edu/radiologyfp/92 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Radiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Authors Jeffrey Landy, Priya Johal, Alexander Sevrukov, Ida Teberian, Jason Shames, Christopher Sebastiano, and Theresa Kaufman This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/radiologyfp/92 Radiology Case Reports 15 (2020) 2401–2405 Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/radcr Case Report Malignant phyllodes tumor with extensive lipomatous differentiation ∗ Jeffrey Landy MD , Priya Johal MD, Alexander Sevrukov MD, Ida Teberian MD, Jason Shames MD, Christopher Sebastiano MD, Theresa Kaufman DO Thomas Jefferson University Hospital, 111 S. 11th St., Philadelphia, PA 19107 a r t i c l e i n f o a b s t r a c t Article history: Phyllodes tumors are uncommon neoplasms of the breast. Lipomatous differentiation of Received 23 July 2020 malignant phyllodes tumor is a rare stromal alteration of this fibroepithelial tumor, demon- Accepted 12 August 2020 strated as a fat-containing mass on imaging. We present the case of a 46-year-old woman who was diagnosed with a malignant phyllodes tumor of the breast that demonstrated ex- tensive lipomatous differentiation. Keywords: © 2020 Published by Elsevier Inc. on behalf of University of Washington. Phyllodes This is an open access article under the CC BY-NC-ND license Lipomatous differentiation ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) Fibroadenoma Hamartoma Introduction Case report Phyllodes tumor is a rare fibroepithelial neoplasm of the A 46-year-old woman presented for a screening mammogram, breast, more commonly seen in middle-aged women. The reporting a new lump in her upper outer left breast. Mammo- most common presentation is that of a rapidly growing, pal- gram demonstrated a 35-mm fat-containing, oval mass with pable mass. Phyllodes tumors may be classified as benign, ma- circumscribed margins in the 3 o’clock left breast, 9 cm from lignant, or borderline, a distinction which is largely made his- the nipple which corresponded to the palpable mass reported tologically based on the degree of nuclear atypia, tumor bor- by the patient ( Figs. 1 and 2 ). Breast sonography revealed an der, stromal cellularity, and mitotic activity. While Ductal car- oval, parallel, hyperechoic mass in the left breast, correspond- cinoma in situ (DCIS), Lobular carcinoma in situ (LCIS), or inva- ing to the mammographic finding and region of palpable con- sive cancers may arise from the epithelial component of phyl- cern ( Figs. 3 and 4 ). lodes tumors, the stromal component may contain heterolo- The patient underwent an ultrasound-guided core nee- gous elements such as adipose tissue, cartilage, bone, skeletal dle biopsy which showed fragments of fibroadipose tissue muscle, and fibrous tissue. Lipomatous differentiation within containing multiple foci of hypercellular spindle cell prolif- a phyllodes tumor is an uncommon stromal alteration. Herein, eration associated with benign ducts and focal fat necrosis. we present a case of malignant phyllodes tumor with exten- There was significant nuclear atypia and a few mitoses were sive lipomatous differentiation in a 46-year-old woman. present. Immunohistochemical stains showed that the spin- ∗ Corresponding author. E-mail address: [email protected] (J. Landy MD). https://doi.org/10.1016/j.radcr.2020.08.023 1930-0433/© 2020 Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 2402 Radiology Case Reports 15 (2020) 2401–2405 Fig. 1 – Craniocaudal digital breast tomosynthesis view of the left breast demonstrate a fat-containing, oval mass with circumscribed margins. dle cells were negative for CK5/6, p63, CAM5.2, SMA, desmin, Fig. 2 – Mediolateral oblique synthetic digital breast AE1/AE3, CD163, nuclear beta catenin, SMA, and CD34. The Ki- tomosynthesis view of the left breast demonstrate a 67 proliferation index was high (estimated ˜40%-60%). A defini- fat-containing, oval mass with circumscribed margins. tive pathologic diagnosis was precluded in this specimen, and excision was recommended due to the presence of atypia, hy- percellularity, and proliferation index ( Fig. 5, 6 and 7 ). Subsequent wire localization excisional biopsy was per- formed. Microscopic examination revealed a biphasic hyper- Certain imaging features of a phyllodes tumor may suggest cellular lesion with both stromal and distorted glandular el- malignancy. Partially obscured or indistinct tumor margins ements and extensive lipomatous differentiation. Although are more often seen in malignant phyllodes tumors. Tumor mostly well circumscribed, some infiltration into the sur- size of greater than 3 cm is associated with a higher likelihood rounding tissue was identified as well as nuclear atypia and an of malignancy [1] . MRI may demonstrate restricted diffusion, increased mitotic rate (10 mitoses/High-power field (HPF)). The suggestive of a malignant phyllodes tumor. Focal intralesional diagnosis of malignant phyllodes tumor with lipomatous dif- cysts are more common in malignant phyllodes tumors and ferentiation was made based on these findings. Fluorescence are manifest on MRI by hyperintense slit-like spaces on in situ hybridization (FISH) was performed and was negative T2-weighted images. While washout enhancement kinetics for Mouse double minute 2 (MDM2), suggesting that the lipo- are suspicious for malignancy, up to 35% of the malignant matous component itself was not malignant (ie, liposarcoma). phyllodes tumors may demonstrate persistent enhancement kinetics more typically associated with benignity [2] . Histologically, phyllodes tumors are biphasic, consisting of a hypercellular stromal component and cleft-like spaces Discussion lined by epithelium, often forming a leaflike pattern [3] . Suf- ficient sampling is necessary if the lesion appears ill defined Phyllodes tumors often present as a firm, palpable, mobile (approximately 1 section per centimeter) and the tumor is mass that demonstrates rapid growth often over a course classified based on the area of highest cellularity or floridity of just several weeks. Imaging typically demonstrates a cir- [4] . The tumors are divided into benign, intermediate, and ma- cumscribed, high density mass with oval, round, or lobulated lignant patterns based on several histologic characteristics, shape. The mean size is 4-5 cm but can range from 1 to 20 cm. including an infiltrative margin, stromal overgrowth, mitotic Associated calcifications are rare [1] . count, amount of hypercellularity, and atypia [3] . Radiology Case Reports 15 (2020) 2401–2405 2403 Fig. 3 – Radial grayscale ultrasound image of the left breast demonstrate an oval, parallel, hyperechoic mass corresponding to the mass seen on mammogram. Fig. 4 –Power Doppler ultrasound image of the left breast demonstrate an oval, parallel, hyperechoic mass corresponding to the mass seen on mammogram, without significant internal vascularity. Malignant transformation may occur in up to 20% of phyl- rare [9] . Powell and Rosen reported 14 cases of adipose differ- lodes tumors, often within its stromal component. Of those entiation, 13 of which were malignant [10] . with malignant stromal differentiation, most display fibrosar- One of the main differential considerations for a large, comatous components. Adipose stromal differentiation may rapidly growing mass is fibroadenoma. As opposed to phyl- also occur, ranging from mature fat to liposarcomatous trans- lodes tumors, fibroadenomas are more likely to contain calcifi- formation [5–8] . However, pure lipomatous differentiation is cations, are less likely to contain cystic spaces and are usually 2404 Radiology Case Reports 15 (2020) 2401–2405 Fig. 5 –At 5 × magnification, the lesion demonstrates a hypercellular stroma and distorted glandular elements with extensive
Load more

Recommended publications
  • Understanding Your Pathology Report: Benign Breast Conditions
    cancer.org | 1.800.227.2345 Understanding Your Pathology Report: Benign Breast Conditions When your breast was biopsied, the samples taken were studied under the microscope by a specialized doctor with many years of training called a pathologist. The pathologist sends your doctor a report that gives a diagnosis for each sample taken. Information in this report will be used to help manage your care. The questions and answers that follow are meant to help you understand medical language you might find in the pathology report from a breast biopsy1, such as a needle biopsy or an excision biopsy. In a needle biopsy, a hollow needle is used to remove a sample of an abnormal area. An excision biopsy removes the entire abnormal area, often with some of the surrounding normal tissue. An excision biopsy is much like a type of breast-conserving surgery2 called a lumpectomy. What does it mean if my report uses any of the following terms: adenosis, sclerosing adenosis, apocrine metaplasia, cysts, columnar cell change, columnar cell hyperplasia, collagenous spherulosis, duct ectasia, columnar alteration with prominent apical snouts and secretions (CAPSS), papillomatosis, or fibrocystic changes? All of these are terms that describe benign (non-cancerous) changes that the pathologist might see under the microscope. They do not need to be treated. They are of no concern when found along with cancer. More information about many of these can be found in Non-Cancerous Breast Conditions3. What does it mean if my report says fat necrosis? Fat necrosis is a benign condition that is not linked to cancer risk.
    [Show full text]
  • Bilateral Giant Juvenile Fibroadenomas of Breasts: a Case Report
    SAGE-Hindawi Access to Research Pathology Research International Volume 2011, Article ID 482046, 4 pages doi:10.4061/2011/482046 Case Report Bilateral Giant Juvenile Fibroadenomas of Breasts: A Case Report D. B. Nikumbh, S. R. Desai, P. S. Madan, N. J. Patil, and J. V. Wader Department of Pathology, Krishna Institute of Medical Sciences, Karad, District Satara, Maharashtra 415110, India Correspondence should be addressed to D. B. Nikumbh, drdhirajnikumbh@rediffmail.com Received 9 October 2010; Revised 4 April 2011; Accepted 7 April 2011 Academic Editor: Elizabeth Wiley Copyright © 2011 D. B. Nikumbh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Juvenile fibroadenoma constitutes only 4% of the total fibroadenomas. The incidence of giant juvenile fibroadenomas is found to be only 0.5% of all the fibroadenomas. Bilateral giant juvenile fibroadenomas are extremely rare, and only four cases have been reported in the literature. Tothe best of our knowledge, we are presenting the fifth case of bilateral giant juvenile fibroadenomas in a 12-year-old prepubertal girl. The diagnosis was made on fine-needle aspiration cytology which was confirmed on histopathology. In this paper, we present this rare case to illustrate the diagnosis and management of this tumour and to emphasize that these tumours are almost always benign and should be treated with breast-conserving surgery to provide a healthy physical and social life to the patient. 1. Introduction both the breasts were seen, which were firm in consistency.
    [Show full text]
  • Non-Cancerous Breast Conditions Fibrosis and Simple Cysts in The
    cancer.org | 1.800.227.2345 Non-cancerous Breast Conditions ● Fibrosis and Simple Cysts ● Ductal or Lobular Hyperplasia ● Lobular Carcinoma in Situ (LCIS) ● Adenosis ● Fibroadenomas ● Phyllodes Tumors ● Intraductal Papillomas ● Granular Cell Tumors ● Fat Necrosis and Oil Cysts ● Mastitis ● Duct Ectasia ● Other Non-cancerous Breast Conditions Fibrosis and Simple Cysts in the Breast Many breast lumps turn out to be caused by fibrosis and/or cysts, which are non- cancerous (benign) changes in breast tissue that many women get at some time in their lives. These changes are sometimes called fibrocystic changes, and used to be called fibrocystic disease. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 Fibrosis and cysts are most common in women of child-bearing age, but they can affect women of any age. They may be found in different parts of the breast and in both breasts at the same time. Fibrosis Fibrosis refers to a large amount of fibrous tissue, the same tissue that ligaments and scar tissue are made of. Areas of fibrosis feel rubbery, firm, or hard to the touch. Cysts Cysts are fluid-filled, round or oval sacs within the breasts. They are often felt as a round, movable lump, which might also be tender to the touch. They are most often found in women in their 40s, but they can occur in women of any age. Monthly hormone changes often cause cysts to get bigger and become painful and sometimes more noticeable just before the menstrual period. Cysts begin when fluid starts to build up inside the breast glands. Microcysts (tiny, microscopic cysts) are too small to feel and are found only when tissue is looked at under a microscope.
    [Show full text]
  • Chapter 10 Gene Expression Signatures of Breast Phyllodes
    Chapter 10 Gene expression signatures of breast phyllodes tumor and fibroadenoma A Kuijper E Korsching C Kersting E van der Wall H Bürger PJ van Diest Manuscript Chapter 10 Abstract Phyllodes tumor (PT) and fibroadenoma share morphological similarities but display different clinical behavior. In addition, fibroadenoma may progress to PT by monoclonal stromal expansion. We compared transcriptome-wide levels of gene expression of both tumors and normal breast tissue in order to gain insight into the molecular mechanisms driving development and progression of fibroepithelial tumors. We used the Affymetrix GeneChip HG-U133A 2.0, which contains more than 22000 probe-sets, to examine gene expression profiles of fibroadenomas (n=5) and phyllodes tumors (n=8). Profiles were compared to signatures of normal breast as well. Immunohistochemical validation of microarray data was performed for two genes, c-kit and CXCR4, on tissue microarrays (TMA) composed of 58 PTs and 167 fibroadenomas. We detected many novel genes with a possible role in the pathogenesis of fibroepithelial tumors. IGF-2 showed strong upregulation in fibroadenoma when compared to normal tissue. Among the genes displaying strongest downregulation in fibroadenoma were several genes involved in steroid binding and metabolism (SCGB1D2, SCGB2A2, SCGB2A1, SULT2B1) and galactose metabolism (LALBA). In comparison to the normal breast, PT showed downregulation of DNA repair genes (POLL, RECQL, TP73L), cell adhesion genes (PKP1, CX3CL1, FAT2, DSC1), transcription factors (ETV4, TP73L, SOX10, KLF5, BCL11B) and growth factors (TGFA, EGF, PDGFC). As compared to fibroadenoma, PT displayed upregulation of 26 genes and downregulation of 52 genes. Downregulation was found of genes involved in transcription (EGR1, ELF5, LZTS1), cell adhesion (JAM2, PCDH11X, CX3CL1), apoptosis (TNFSF8, PHLDA1) and Wnt signaling (FRZB, SFRP1).
    [Show full text]
  • Intraoral Lipoma: a Case Report
    Hindawi Publishing Corporation Case Reports in Medicine Volume 2014, Article ID 480130, 4 pages http://dx.doi.org/10.1155/2014/480130 Case Report Intraoral Lipoma: A Case Report L. K. Surej Kumar, Nikhil Mathew Kurien, Varun B. Raghavan, P. Varun Menon, and Sherin A. Khalam Department of Oral & Maxillofacial Surgery, PMS College of Dental Science & Research, Golden Hills, Vattappara, Venkode, Thiruvananthapuram 695028, India Correspondence should be addressed to P. Varun Menon; [email protected] Received 13 September 2013; Accepted 19 December 2013; Published 30 January 2014 Academic Editor: David W. Eisele Copyright © 2014 L. K. Surej Kumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Lipomas are rare in oral and maxillofacial regions although they are the most common tumours of mesenchymal origin in human body. The etiology remains unclear. Various different theories explain the pathogenesis of this adipose tissue tumour andalso different histological variants of oral lipoma have been given in literature. A case of intraoral lipoma occurring in mental region in a 77-year-old male is reported along with review of the literature. Wide surgical excision was performed and two-year followup showed excellent healing without any recurrence. Lipomas are benign soft tissue neoplasm of mature adipose tissue seen as a common entity in the head and neck region. Intraoral lipomas are a rare entity which may be noticed only during routine dental examinations. Most of them rarely cause pain, resulting in delay to seek treatment.
    [Show full text]
  • New Jersey State Cancer Registry List of Reportable Diseases and Conditions Effective Date March 10, 2011; Revised March 2019
    New Jersey State Cancer Registry List of reportable diseases and conditions Effective date March 10, 2011; Revised March 2019 General Rules for Reportability (a) If a diagnosis includes any of the following words, every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report the case to the Department in accordance with the provisions of N.J.A.C. 8:57A. Cancer; Carcinoma; Adenocarcinoma; Carcinoid tumor; Leukemia; Lymphoma; Malignant; and/or Sarcoma (b) Every New Jersey health care facility, physician, dentist, other health care provider or independent clinical laboratory shall report any case having a diagnosis listed at (g) below and which contains any of the following terms in the final diagnosis to the Department in accordance with the provisions of N.J.A.C. 8:57A. Apparent(ly); Appears; Compatible/Compatible with; Consistent with; Favors; Malignant appearing; Most likely; Presumed; Probable; Suspect(ed); Suspicious (for); and/or Typical (of) (c) Basal cell carcinomas and squamous cell carcinomas of the skin are NOT reportable, except when they are diagnosed in the labia, clitoris, vulva, prepuce, penis or scrotum. (d) Carcinoma in situ of the cervix and/or cervical squamous intraepithelial neoplasia III (CIN III) are NOT reportable. (e) Insofar as soft tissue tumors can arise in almost any body site, the primary site of the soft tissue tumor shall also be examined for any questionable neoplasm. NJSCR REPORTABILITY LIST – 2019 1 (f) If any uncertainty regarding the reporting of a particular case exists, the health care facility, physician, dentist, other health care provider or independent clinical laboratory shall contact the Department for guidance at (609) 633‐0500 or view information on the following website http://www.nj.gov/health/ces/njscr.shtml.
    [Show full text]
  • A Five-Gene Reverse Transcription-PCR Assay for Pre-Operative
    Tan et al. Breast Cancer Research (2016) 18:31 DOI 10.1186/s13058-016-0692-6 RESEARCH ARTICLE Open Access A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions Wai Jin Tan1, Igor Cima1, Yukti Choudhury1, Xiaona Wei1, Jeffrey Chun Tatt Lim2, Aye Aye Thike2, Min-Han Tan1* and Puay Hoon Tan2,3* Abstract Background: Breast fibroepithelial lesions are biphasic tumors and include fibroadenomas and phyllodes tumors. Preoperative distinction between fibroadenomas and phyllodes tumors is pivotal to clinical management. Fibroadenomas are clinically benign while phyllodes tumors are more unpredictable in biological behavior, with potential for recurrence. Differentiating the tumors may be challenging when they have overlapping clinical and histological features especially on core biopsies. Current molecular and immunohistochemical techniques have a limited role in the diagnosis of breast fibroepithelial lesions. We aimed to develop a practical molecular test to aid in distinguishing fibroadenomas from phyllodes tumors in the pre-operative setting. Methods: We profiled the transcriptome of a training set of 48 formalin-fixed, paraffin-embedded fibroadenomas and phyllodes tumors and further designed 43 quantitative polymerase chain reaction (qPCR) assays to verify differentially expressed genes. Using machine learning to build predictive regression models, we selected a five-gene transcript set (ABCA8, APOD, CCL19, FN1,andPRAME) to discriminate between fibroadenomas and phyllodes tumors. We validated our assay in an independent cohort of 230 core biopsies obtained pre-operatively. Results: Overall, the assay accurately classified 92.6 % of the samples (AUC = 0.948, 95 % CI 0.913–0.983, p = 2.51E-19), with a sensitivity of 82.9 % and specificity of 94.7 %.
    [Show full text]
  • Malignant Phyllodes Tumors Display Mesenchymal Stem Cell Features and Aldehyde Dehydrogenase
    Lin et al. Breast Cancer Research 2014, 16:R29 http://breast-cancer-research.com/content/16/2/R29 RESEARCH ARTICLE Open Access Malignant phyllodes tumors display mesenchymal stem cell features and aldehyde dehydrogenase/ disialoganglioside identify their tumor stem cells Jin-Jin Lin1,2, Chiun-Sheng Huang3, John Yu1, Guo-Shiou Liao4, Huang-Chun Lien5, Jung-Tung Hung6, Ruey-Jen Lin6, Fen-Pi Chou2, Kun-Tu Yeh7* and Alice L Yu1,6* Abstract Introduction: Although breast phyllodes tumors are rare, there is no effective therapy other than surgery. Little is known about their tumor biology. A malignant phyllodes tumor contains heterologous stromal elements, and can transform into rhabdomyosarcoma, liposarcoma and osteosarcoma. These versatile properties prompted us to explore their possible relationship to mesenchymal stem cells (MSCs) and to search for the presence of cancer stem cells (CSCs) in phyllodes tumors. Methods: Paraffin sections of malignant phyllodes tumors were examined for various markers by immunohistochemical staining. Xenografts of human primary phyllodes tumors were established by injecting freshly isolated tumor cells into the mammary fat pad of non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice. To search for CSCs, xenografted tumor cells were sorted into various subpopulations by flow cytometry and examined for their in vitro mammosphere forming capacity, in vivo tumorigenicity in NOD-SCID mice and their ability to undergo differentiation. Results: Immunohistochemical analysis revealed the expression of the following 10 markers: CD44, CD29, CD106, CD166, CD105, CD90, disialoganglioside (GD2), CD117, Aldehyde dehydrogenase 1 (ALDH), and Oct-4, and 7 clinically relevant markers (CD10, CD34, p53, p63, Ki-67, Bcl-2, vimentin, and Globo H) in all 51 malignant phyllodes tumors examined, albeit to different extents.
    [Show full text]
  • WO 2018/035138 Al 22 February 2018 (22.02.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/035138 Al 22 February 2018 (22.02.2018) W !P O PCT (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, A61L 27/36 (2006.01) A01K 67/027 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. C12N S/00 (2006.01) C12N 5/077 (2010.01) (84) Designated States (unless otherwise indicated, for every C12N 5/071 (2010.01) G01N 33/50 (2006.01) kind of regional protection available): ARIPO (BW, GH, C12N 5/09 (2010.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (21) International Application Number: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, PCT/US20 17/046983 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (22) International Filing Date: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 15 August 2017 (15.08.2017) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (25) Filing Language: English KM, ML, MR, NE, SN, TD, TG). (26) Publication Language: English Published: (30) Priority Data: — with international search report (Art. 21(3)) 62/375,016 15 August 2016 (15.08.2016) US 62/430,015 05 December 2016 (05.12.2016) US (71) Applicants: ORGANOVO, INC.
    [Show full text]
  • Surgical Excision and Oncoplastic Breast Surgery in 32 Patients with Benign Phyllodes Tumors Jie Ren1†, Liyan Jin1,2†, Bingjing Leng1, Rongkuan Hu1 and Guoqin Jiang1*
    Ren et al. World Journal of Surgical Oncology (2018) 16:153 https://doi.org/10.1186/s12957-018-1453-z RESEARCH Open Access Surgical excision and oncoplastic breast surgery in 32 patients with benign phyllodes tumors Jie Ren1†, Liyan Jin1,2†, Bingjing Leng1, Rongkuan Hu1 and Guoqin Jiang1* Abstract Background: The purpose of this study was to assess the effectiveness and safety in patients with benign phyllodes after performing local excision and following with intra-operative breast flap reconstruction. Methods: Patients (n = 32) with eligible breast cystosarcoma phyllodes underwent wide local excision followed by intra-operative breast flap reconstruction. Primary outcome measures included average operative time, length of in-hospital stay, postoperative recurrence, and intra-operative and postoperative complications. Results: Thirty-two patients who underwent surgical excision and oncoplastic breast surgery were evaluated using the BCCT.core software. A satisfactory symmetrical breast shape was achieved. The average operative time was 56.3 ± 8.2 min. The average postoperative duration of hospitalization was 3.7 ± 1.2 days. While there was no breast disease recurred during the 1 to 8-year follow-up period. Conclusions: Wide local excision accompanied by intra-operative breast flap reconstruction could be adopted for removing benign phyllodes tumors while retaining the basic shape of the breast. Keywords: Phyllodes tumor, Core needle biopsy, Oncoplastic breast surgery, Breast reconstruction Background breast tumor was determined by preoperative ultrasonog- Phyllodes tumor is a very rare breast tumor that com- raphy and magnetic resonance imaging (MRI) in all prises 0.3–1% of all primary breast tumors. Phyllodes patients (Fig. 1).
    [Show full text]
  • Oncoplastic Approach to Giant Benign Breast Tumors Presenting As Unilateral Macromastia
    Published online: 2020-08-26 THIEME Case Report 439 Oncoplastic Approach to Giant Benign Breast Tumors Presenting as Unilateral Macromastia Lekshmi Malathi1, 1Department of Plastic Surgery, Government Medical College, Address for correspondence Lekshmi Malathi, MS, MCh, DNB, Kottayam, Kerala, India Department of Plastic Surgery, Government Medical College, Gandhinagar, Kottayam-686008, Kerala, India (e-mail: [email protected]). Indian J Plast Surg:2020;53:439–441 Abstract Benign breast tumors attaining large size constitute an important cause of unilateral macromastia. Their usual treatment involves enucleation or excision with a margin based on pathology and waiting for spontaneous retraction of skin envelope. In very Keywords large tumors, this will leave the residual breast deflated and unaesthetic, with spon- ► giant benign tumors taneous skin retraction giving unpredictable results. Application of the principles of ► oncoplasty oncoplastic surgery are helpful in this situation. Here, we present two cases of benign ► unilateral giant tumors—a giant fibroadenoma and a giant lipoma—managed by reduction mam- macromastia maplasty approach to restore the breast symmetry and aesthetics. Introduction Case Report and Technique Symmetry is of utmost importance in paired organs such as Case 1 breasts. The commonest cause of breast asymmetry or uni- A 34-year-old multiparous lady presented with right-sided lateral hypertrophy is an unequal physiological hypertrophy. macromastia for a period of 2 years. The enlargement was However, a neoplastic etiology should be thought of when gradual and asymptomatic, except for a heavy feeling on the there is marked asymmetry or architectural distortion.1 affected side. On examination, there was significant asym- The commonly encountered benign giant tumors are giant metry and a few dilated veins over the affected breast.
    [Show full text]
  • WO 2014/080291 A2 30 May 20 14 (30.05.2014) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/080291 A2 30 May 20 14 (30.05.2014) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 401/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IB20 13/003 126 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 20 November 2013 (20.1 1.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/729,108 2 1 November 2012 (21. 11.2012) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: RVX THERAPEUTICS INC. [CA/CA]; 202, kind of regional protection available): ARIPO (BW, GH, 279 Midpark Way SE, Calgary, Alberta T2X 1M2 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: FAIRFAX, David, John; 72 McCormack TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Road, Slingerlands, NY 12159 (US).
    [Show full text]